The following represents disclosure information provided by authors of this abstract. The Breast Cancer Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of molecular (BluePrint and MammaPrint) and pathological subtypes for breast cancer among the first 800 patients from the EORTC 10041/BIG 3-04 (MINDACT) trial.
Giuseppe Viale
No relevant relationships to disclose
Leen Slaets
No relevant relationships to disclose
Femke De Snoo
Employment or Leadership Position - Agendia
Laura J. van 't Veer
Employment or Leadership Position - Agendia
Stock Ownership - Agendia
Emiel J. Rutgers
No relevant relationships to disclose
Jan Bogaerts
No relevant relationships to disclose
Lisette Stork-Sloots
Employment or Leadership Position - Agendia
Kristel Engelen
No relevant relationships to disclose
Leila Russo
No relevant relationships to disclose
Patrizia Dell'Orto
No relevant relationships to disclose
Fatima Cardoso
No relevant relationships to disclose
Martine J. Piccart-Gebhart
No relevant relationships to disclose